| Biotechnology Industry | Healthcare Sector | Andrey Semechkin CEO | OTCQX Exchange | 460378201 CUSIP |
| US Country | 33 Employees | - Last Dividend | 29 Jul 2015 Last Split | - IPO Date |
International Stem Cell Corporation is a clinical stage biotechnology firm that has laid its focus on the development of therapeutic and biomedical products across a global scale including the United States, Asia, and Europe. The company is known for its pioneering work in the field of regenerative medicine, especially with its neural stem cell program, ISC-hpNSC, which has reached completion in Phase I clinical trial targeting Parkinson's disease, and showing promising potential for applications in stroke and traumatic brain injury treatments. Founded in 2001, the company has its headquarters in San Diego, California, marking its presence as an influential player in the biotechnology and stem cell research industries.
This program is at the forefront of the company's initiatives, having completed a Phase I clinical trial for Parkinson's disease treatment, with prospects for extension into stroke and traumatic brain injury therapies.
In addition to its medical therapies, the company also offers a line of anti-aging skin care products, which includes ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, Eye Firming Complex, Neck Firming Complex, Advanced Aqueous Treatment, Collagen Booster, Elastin Booster, and Brightening Toner specifically formulated to rejuvenate skin and delay signs of aging.
The company provides an extensive range of human cell culture products tailored for various research and medical purposes. This includes human skin cells for skin disease, toxicology, and wound healing studies; heart and blood vessel cells for cardiovascular disease and cancer research; bronchial and tracheal cell lines for toxicity, cystic fibrosis, asthma, and pathogenesis studies; mammary epithelial cell lines for breast cancer research; adult stem cells and reagents for regenerative medicine; prostate cells for prostate disease studies; renal and bladder cells for renal and bladder disease research; corneal cells for corneal disease studies; female reproductive system cells; skeletal muscle cells for a variety of biological and medical research purposes; and other vital cell culture reagents and supplements for the maintenance, growth, and analysis of these human cell cultures.